In vivo CAR T-cell therapy KLN-1010 achieved a 100% overall response rate in all 18 multiple myeloma patients in a Phase I trial.
- In the news
CAR-T cell therapy research
Moving in Blood, Cancer Discovery, Cell, Cellular & molecular immunology.
- Moved this week
- 7
Rebuilt
Moved this week
China approves satricabtagene autoleucel, the first CAR T-cell therapy for solid tumors, showing promise in gastric and gastro-esophageal cancers with improved survival metrics.
- In the news
In vivo CAR gene therapy shows promising clinical proof of concept with potential to overcome ex vivo manufacturing limitations.
Gut metabolites have opposing effects on CAR-T cell therapy outcomes, with valeric acid improving and indole metabolites impairing treatment efficacy.
γδ and αβ CAR-T cells show similar cytotoxicity but differ significantly in metabolic and signaling pathways, with γδ cells exhibiting lower glycolytic and oxidative capacities.
Arlocabtagene autoleucel achieves an 87% overall response rate with durable responses in heavily pretreated relapsed/refractory multiple myeloma patients.
- Open access
- 5 cites
CD19 CAR T-cell therapy without lymphodepletion shows promising safety and efficacy in pemphigus vulgaris patients, with significant disease improvement in all four cases.
- Open access
- 4 cites
Latest in CAR-T cell therapy research
Newest first · last 60 days
The ITCC-P4 platform developed 353 pediatric cancer PDX models, enabling preclinical testing and biomarker discovery for high-risk solid tumors.
- Open access
TLR9 agonists enhance adoptive T cell therapy by activating a B cell-CD2 costimulatory pathway, leading to improved tumor control and T cell function.
- Open access
Synthetic pH-responsive membranolytic peptide induces immunogenic cell death, boosting immune checkpoint therapy efficacy in tumors with 50% enhanced response.
CAR T cells targeting surface U5 snRNP200, an RNA-binding protein absent from normal hematopoietic precursors, effectively treat AML and B-cell ALL with improved safety.
- Open access
CAR T cell therapy targeting CD19 can induce long-term remission of intestinal inflammation in ulcerative colitis, revealing a new therapeutic avenue for IBD.
- 1 cites
Venetoclax-controlled DROP-CAR T cells effectively regulate tumor targeting and reduce off-tumor toxicity through dose-dependent cell-cell interaction modulation.
- Open access
- 2 cites
CAR-T cell therapies and cancer nanovaccines show promise but face distinct translational challenges, with recent advances highlighting their potential to reshape cancer treatment.
- Open access
Intratumoral T cell activation can eradicate tumors without tumor-specific T cell receptors, relying on paracrine signaling and innate immune responses.
CytoVI enables comprehensive analysis of antibody-based single-cell data, accurately modeling 350 proteins and revealing disease-related immune cell states.
- Open access
Harmonizing trial design and biomarker integration is essential to improve personalized treatment for large B-cell lymphoma patients.
Mucosal CAR-T cells persist and cause inflammatory remodeling in enterocolitis, with 10 patients showing severe mucosal dysregulation after BCMA CAR-T therapy.
mRNA-encoded CD19-targeting T cell engager achieves complete B cell depletion and durable platelet recovery in refractory immune thrombocytopenia with minimal safety concerns.
- Open access
Heterobifunctional protein binders achieve cell-type-specific targeting with subnanomolar potency via FKBP12-dependent enrichment.
- Open access
PreGame identifies tumour-reactive γδ T-cell receptors with broad reactivity, revealing potential for universal immunotherapy in multiple myeloma and other cancers.
- Open access
Combining cyclophosphamide with immune checkpoint blockade expands effector CD8+ T cell clones, delaying tumor progression in multiple cancer models.
Elevated NF-κB activity in CD4 CAR-T cells predicts durable responses and improved survival in multiple myeloma patients treated with ide-cel.
CD4+CD25+FOXP3+ regulatory T cells significantly reduce graft-versus-host disease risk in allogeneic hematopoietic cell transplantation.
Localized PD-1 CAR T therapy effectively reprograms neuroinflammation, reducing CNS inflammation and improving outcomes in murine models of multiple sclerosis.
Arlocabtagene autoleucel achieves an 87% overall response rate with durable responses in heavily pretreated relapsed/refractory multiple myeloma patients.
- Open access
- 5 cites
Allogeneic BCMA CAR T cells armed with NKG2A receptor (CT0590) effectively resist host NK cell attacks and show durable responses in multiple myeloma patients.
CRISPR-Cas9 strategies enable precise reprogramming of immune responses to treat cancer and autoimmune diseases.
- Open access
- 2 cites
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1738
- Environ Res483
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ199
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- J Exp Bot115
- Curr Biol112
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4